Thursday, 15 October 2026European Markets

IDI Stock Bullish Momentum With A 15% Rise In The Last 5 Sessions

Loading stream...

(vianews) - shares of idi (cac 40: idip.pa) jumped by a staggering 15.25% in 5 sessions from €56.4 to €65.00 at 14:54 est on wednesday, after three consecutive sessions in a row of gains. cac 40 is dropping 0.42% to €7,263.62, after two sequential sessions in a row of losses.

about idi

idi is a private equity firm specializing in leveraged buyouts, expansion capital, middle market, growth capital, acquisition of significant holdings in listed small and medium companies and secondary private equity portfolios, mezzanine financing, loans senior to senior debt, discounted leveraged buyouts loans in mature companies and through co-investments in pre-ipo financing. within fund of fund investments, the firm invests in private equity funds and hedge funds. it seeks to invest in all sectors. the firm primarily seeks to invest in france and european developed markets. it generally makes an equity investment between €25 million ($27.61 million) and €70 million ($77.31 million) and invests in companies with an enterprise value ranging between €10 million ($11.04 million) and €300 million ($331.34 million) with the capacity to exceed this limit on a case-by-case basis and invests between €5 million ($5.52 million) and €25 million ($27.61 million) per deal. it seeks to invest in funds with a fund size between $50 million and €300 million ($331.34 million). the firm takes majority and minority stakes in companies with a focus on majority positions in small and medium-sized companies acquiring through leveraged buyouts. the firm mainly invests through its own capital in both direct and fund of funds investments. the firm prefers to invest from its balance sheet. idi was founded in 1970 and is based in paris, france with an additional office in paris, france.

earnings per share

as for profitability, idi has a trailing twelve months eps of €10.31.

pe ratio

idi has a trailing twelve months price to earnings ratio of 6.3. meaning, the purchaser of the share is investing €6.3 for every euro of annual earnings.

volatility

idi's last week, last month's, and last quarter's current intraday variation average was 5.28%, 0.98%, and 1.39%.

idi's highest amplitude of average volatility was 5.28% (last week), 1.90% (last month), and 1.39% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, idi's stock is considered to be oversold (<=20).

more news about idi (idip.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com